News Image

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Provided By GlobeNewswire

Last update: Feb 25, 2025

 Achieved Q4 2024 and full year 2024 OJEMDAâ„¢ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively

Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments

Read more at globenewswire.com

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (7/25/2025, 8:00:01 PM)

After market: 7.3 +0.07 (+0.97%)

7.23

+0.02 (+0.28%)



Find more stocks in the Stock Screener

Follow ChartMill for more